This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ibrahim, A. S.
Right arrow Articles by Edwards, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ibrahim, A. S.
Right arrow Articles by Edwards, J. E., Jr.

 Previous Article  |  Next Article 

Infection and Immunity, February 2005, p. 999-1005, Vol. 73, No. 2
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.2.999-1005.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Vaccination with Recombinant N-Terminal Domain of Als1p Improves Survival during Murine Disseminated Candidiasis by Enhancing Cell-Mediated, Not Humoral, Immunity

Ashraf S. Ibrahim,1,2* Brad J. Spellberg,1,2 Valentina Avenissian,1 Yue Fu,1,2 Scott G. Filler,1,2 and John E. Edwards Jr.1,2

Department of Medicine, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, Torrance,1 David Geffen School of Medicine at UCLA, Los Angeles, California2

Received 26 August 2004/ Returned for modification 27 September 2004/ Accepted 12 October 2004

Candida spp. are opportunistic fungal pathogens that are among the most common causes of nosocomial bloodstream infections. The mortality attributable to disseminated candidiasis is 40 to 50% despite antifungal therapy. Clearly, new strategies are needed to prevent this life-threatening infection. Because risk factors for disseminated candidiasis are well defined and frequently of limited duration, vaccination is an appealing prophylactic strategy. We have identified a cell surface protein, Als1p, that mediates adherence of Candida albicans to a variety of human substrates and plastic. Here we report that immunizing BALB/c mice with the recombinant N-terminal domain of Als1p (rAls1p-N) improved survival during a subsequent challenge with a lethal inoculum of C. albicans. The protective 20-µg dose of rAls1p-N significantly increased Candida stimulation of Th1 splenocytes and increased in vivo delayed-type hypersensitivity. In contrast, antibody titers did not correlate with protection. Finally, the vaccine was not protective in T-cell-deficient mice but was protective in B-cell-deficient mice. These data indicate that the mechanism of action of the rAls1p-N vaccine is stimulation of cell-mediated, rather than humoral, immunity against C. albicans. The majority of efforts to date have focused on the development of passive immunization strategies to prevent or treat disseminated candidiasis. In contrast, our results provide proof of principle for vaccination with an adhesin of C. albicans and emphasize the potential for cell-mediated immune modulation as a prophylactic or therapeutic strategy against disseminated candidiasis.

* Corresponding author. Mailing address: Division of Infectious Diseases, Los Angeles Biomedical Institute at Harbor-UCLA Medical Center, 1124 W. Carson St., Torrance, CA 90502. Phone: (310) 222-6424. Fax: (310) 782-2016. E-mail: ibrahim{at}labiomed.org.

Editor: T. R. Kozel

Infection and Immunity, February 2005, p. 999-1005, Vol. 73, No. 2
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.2.999-1005.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Saville, S. P., Lazzell, A. L., Chaturvedi, A. K., Monteagudo, C., Lopez-Ribot, J. L. (2009). Efficacy of a Genetically Engineered Candida albicans tet-NRG1 Strain as an Experimental Live Attenuated Vaccine against Hematogenously Disseminated Candidiasis. CVI 16: 430-432 [Abstract] [Full Text]  
  • Bujdakova, H., Paulovicova, E., Borecka-Melkusova, S., Gasperik, J., Kucharikova, S., Kolecka, A., Lell, C., Jensen, D. B., Wurzner, R., Chorvat, D. Jr, Pichova, I. (2008). Antibody response to the 45 kDa Candida albicans antigen in an animal model and potential role of the antigen in adherence. J Med Microbiol 57: 1466-1472 [Abstract] [Full Text]  
  • Spellberg, B., Ibrahim, A. S., Yeaman, M. R., Lin, L., Fu, Y., Avanesian, V., Bayer, A. S., Filler, S. G., Lipke, P., Otoo, H., Edwards, J. E. Jr. (2008). The Antifungal Vaccine Derived from the Recombinant N Terminus of Als3p Protects Mice against the Bacterium Staphylococcus aureus. Infect. Immun. 76: 4574-4580 [Abstract] [Full Text]  
  • Lin, L., Ibrahim, A. S., Avanesian, V., Edwards, J. E. Jr., Fu, Y., Baquir, B., Taub, R., Spellberg, B. (2008). Considerable Differences in Vaccine Immunogenicities and Efficacies Related to the Diluent Used for Aluminum Hydroxide Adjuvant. CVI 15: 582-584 [Abstract] [Full Text]  
  • Richard, M. L., Plaine, A. (2007). Comprehensive Analysis of Glycosylphosphatidylinositol-Anchored Proteins in Candida albicans. Eukaryot Cell 6: 119-133 [Full Text]  
  • Ibrahim, A. S., Spellberg, B. J., Avanesian, V., Fu, Y., Edwards, J. E. Jr. (2006). The Anti-Candida Vaccine Based on the Recombinant N-Terminal Domain of Als1p Is Broadly Active against Disseminated Candidiasis.. Infect. Immun. 74: 3039-3041 [Abstract] [Full Text]  
  • Orsborn, K. I., Shubitz, L. F., Peng, T., Kellner, E. M., Orbach, M. J., Haynes, P. A., Galgiani, J. N. (2006). Protein Expression Profiling of Coccidioides posadasii by Two-Dimensional Differential In-Gel Electrophoresis and Evaluation of a Newly Recognized Peroxisomal Matrix Protein as a Recombinant Vaccine Candidate. Infect. Immun. 74: 1865-1872 [Abstract] [Full Text]  
  • Spellberg, B. J., Ibrahim, A. S., Avenissian, V., Filler, S. G., Myers, C. L., Fu, Y., Edwards, J. E. Jr. (2005). The Anti-Candida albicans Vaccine Composed of the Recombinant N Terminus of Als1p Reduces Fungal Burden and Improves Survival in Both Immunocompetent and Immunocompromised Mice. Infect. Immun. 73: 6191-6193 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»